Hit to Lead Account of the Discovery of Bisbenzamide and Related Ureidobenzamide Inhibitors of Rho Kinase
摘要:
A highly selective series of bisbenzamide inhibitors of Rho-associated coiled-coil forming protein kinase (ROCK) and a related ureidoberizamide series, both identified by high throughput screening (HTS), are described. Details of the lilt validation and lead generation process, Including structure-activity relationship (SAR) studies, a selectivity assessment, target-independent profiling (TIP) results, and an analysis of functional activity using a rat aortic ring assay are discussed.
Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.
[EN] RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA RHO KINASE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2008086047A1
公开(公告)日:2008-07-17
[EN] Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma. [FR] L'invention concerne des dérivés d'amide et d'urée substitués utiles comme inhibiteurs de la Rho kinase, lesquels inhibiteurs peuvent être utiles dans le traitement de divers troubles tels que les troubles cardiovasculaires, le cancer, les troubles neurologiques, les néphropathies, l'asthme, le dysfonctionnement érectile et le glaucome.
Hit to Lead Account of the Discovery of Bisbenzamide and Related Ureidobenzamide Inhibitors of Rho Kinase
作者:Tina Morwick、Frank H. Büttner、Charles L. Cywin、Georg Dahmann、Eugene Hickey、Scott Jakes、Paul Kaplita、Mohammed A. Kashem、Steven Kerr、Stanley Kugler、Wang Mao、Daniel Marshall、Zofia Paw、Cheng-Kon Shih、Frank Wu、Erick Young
DOI:10.1021/jm9014263
日期:2010.1.28
A highly selective series of bisbenzamide inhibitors of Rho-associated coiled-coil forming protein kinase (ROCK) and a related ureidoberizamide series, both identified by high throughput screening (HTS), are described. Details of the lilt validation and lead generation process, Including structure-activity relationship (SAR) studies, a selectivity assessment, target-independent profiling (TIP) results, and an analysis of functional activity using a rat aortic ring assay are discussed.